Why the study?
ACEi and ARB treatments increase ACE2 expression, raising concern that hypertensive patients taking these medications may face an increased risk of severe or fatal COVID-19.
Do ACE inhibitors or ARBs increase the risk of severe COVID-19 in patients with hypertension compared to alternative treatments like amlodipine?
Do ACE inhibitors or ARBs increase the risk of severe COVID-19 in patients with hypertension compared to alternative treatments like amlodipine?
Answers are grounded in this paper and cite their sources.
This review hypothesizes that ACEi/ARBs may increase the risk of severe COVID-19 by upregulating ACE2 and suggests switching hypertensive patients to calcium channel blockers like amlodipine.
Worldwide, over 7 million people have been infected due to the pandemic of COVID-19. The comorbidities associated to this disease are: hypertension, diabetes mellitus, obesity, obstructive pulmonary disease (COPD), cardiovascular disease, chronic renal failure, smoking, immunosuppression, and hypertension. Angiotensin-converting enzyme 2 (ACE2) is the functional receptor for SARS-CoV-2. This virus has an S protein that recognizes ACE2 as its receptor to enter the cell. ACE2 is a plasmatic protein expressed in alveolar cells type I, II, fibroblasts, endothelial cells and macrophages. Treatment with inhibitors of the angiotensin-converting enzyme (ACEi) or the receptor antagonist for angiotensin II (ARBs) notably increase the expression of ACE2. Therefore, in patients with these pathologies and treated with these medicines, the risk of developing the COVID-19 in a severe and fatal way could be increased. In Mexico, the major mortality due to COVID-19 is related to hypertension, diabetes mellitus, obesity and being over 65 years of age. Therefore, we suggest that during the SARS-CoV-2 pandemic, patients with hypertension treated with ACEi or ARBs, should receive alternative treatments such as L-type Ca2+ channel blockers (amlodipine) that have not been associated with ACE2 until now. Key words: COVID-19; SARS-CoV-2; captopril; losartan hypertension."
No takes yet. Share an insight, caveat, or question.
A 2020 study conducted a review in COVID-19 and hypertension. ACE inhibitors or ARBs was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: